<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83653">
  <stage>Registered</stage>
  <submitdate>13/09/2010</submitdate>
  <approvaldate>20/09/2010</approvaldate>
  <actrnumber>ACTRN12610000780055</actrnumber>
  <trial_identification>
    <studytitle>Pioglitazone in the treatment of acromegaly</studytitle>
    <scientifictitle>The effects on insulin-like growth factor 1 (IGF-1) and growth hormone levels using Pioglitazone in the treatment of active acromegaly</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acromegaly</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pioglitazone - 1month run in period of 15mg (2 weeks) and  30mg  (2 weeks)orally daily, then target dose of 45mg orally daily for further 3 months</interventions>
    <comparator>N/A - This is a single group study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change in Insulin-like growth factor 1 (IGF-1) - measured on a fasting blood test</outcome>
      <timepoint>after 3 months on maximal dose (45 mg) - outcome to be assessed immediatly after the 3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>change in area under the curve of glucose suppressed growth hormone level</outcome>
      <timepoint>after 3 months on maximal dose (45 mg) - outcome to be assessed immediately after the 3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Active acromegaly - clinical features, elevated IGF-1 and/or non-suppressible growth hormone (&gt;1mcg/L) after 75g oral glucose.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Initiation or discontinuation of octreotide in the last 6 months
Initiation or discontinuation of cabergoline in the last 3 months if treatment caused &gt;20% change in serum IGF-1
Congestive heart failure (New York Heart Association (NYHA)Grade 2 or above)
Current thiozolidinedione use
Current malignancy
Clinical liver disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Referral from responsible endocrinologists.  Eligible patients will be directly contacted and explained about the study verbally and in writing, followed by enrolment of those who are willing to participate by one of the investigators.   No allocations - single-arm/ open-label design</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Auckland district health board</primarysponsorname>
    <primarysponsoraddress>Auckland City Hospital, 2 Park Road, Grafton, Auckland 1010</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>A+ Charitable Trust</fundingname>
      <fundingaddress>A+ Trust office, Level 15 Support building Auckland City Hospital, Park road, Grafton, Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To study the effects of pioglitazone (3 months at maximum dose of 45mg) on disease activity of acromegaly, as measured by IGF-1 level.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Y Ethics Committee (New Zealand)</ethicname>
      <ethicaddress>3rd floor, Bank of New Zaland building 
354 Victoria St
PO Box 1031
Hamilton</ethicaddress>
      <ethicapprovaldate>1/06/2009</ethicapprovaldate>
      <hrec>NTY/09/01/004</hrec>
      <ethicsubmitdate>1/01/2009</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Andrew Grey</name>
      <address>Department of Endocrinology, Level 1, Building 4, Greenlane Clinical Centre, Greenlane West, Auckland</address>
      <phone>+64 9 3074949 ext. 26860</phone>
      <fax />
      <email>a.grey@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Andrew Grey</name>
      <address>Department of Endocrinology, Level 1, Building 4, Greenlane Clinical Centre, Greenlane West, Auckland</address>
      <phone>+64 9 3074949 ext. 26860</phone>
      <fax />
      <email>a.grey@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>David Kim</name>
      <address>Department of Endocrinology, Level 1, Building 4, Greenlane Clinical Centre, Greenlane West , Auckland</address>
      <phone>+64 275 375974</phone>
      <fax />
      <email>dkim@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>